Influenza Vaccine Manufacturing-Abstract

Document Sample
Influenza Vaccine Manufacturing-Abstract Powered By Docstoc
					                                                                               A Service of Decision Resources


      Discovery and Innovation: Technologies, Strategies, and Dealmaking
                Barbara M. Bolten, M.S., M.B.A., Senior Program Manager




      Influenza Vaccine Manufacturing: Can New
      Technologies Open the Production Bottleneck?
      Barbara M. Bolten, M.S., M.B.A.
      Decision Resources



Abstract
  Introduction:
  With the threat of swine flu in 2009 came vaccine shortages, long lines at distribution centers, and frustrated
  consumers. New technologies for manufacturing flu vaccines could increase the speed and efficiency of produc-
  ing vaccines and help to avoid these problems. The European Commission’s approval of Novartis’s Optaflu in
  2007 was a significant step forward for cell-based production methods, and many competitors are jumping into
  the race to develop the next generation of influenza vaccines.

  Questions Answered in This Report:
    • Pandemic influenza threats and outbreaks have had a dramatic impact on the overall influenza vaccine mar-
      ket. What fundamental changes to the dynamics of the marketplace occurred as a result of the H5N1
      avian influenza threat? How did governments respond to the 2009 A/H1N1 pandemic? How did this
      outbreak affect vaccine manufacturers?
    • The manufacture of influenza vaccines is based on antiquated methods initially developed in the 1940s.
      What new methods are being implemented to increase the efficiency and speed of manufacturing
      influenza vaccine? Which companies are leading this trend?
    • The drive to create new manufacturing methods is prompting innovative development efforts throughout
      the industry. What cutting-edge technologies are most advanced in development? Which companies
      are investing in and developing these technologies?
    • Collaboration among pharmaceutical companies and biotech companies as well as government support and
      participation are key to accelerating the development of new vaccine manufacturing technologies. Which
      companies are involved in influenza-vaccine-related dealmaking? How is the U.S. government pro-
      moting and supporting influenza vaccine development?




                                 Decision Resources • 260 Charles Street, Waltham, Massachusetts 02453
                              • Tel +1.781.296.2500 • Fax +1.781.296.2550 • www.decisionresources.com •
           For questions regarding this report, contact: Barbara Bolten Tel +1.781.296.2579 • E-mail: bbolten@dresources.com
          For questions regarding consulting, contact: Jim McDermott Tel +1.781.296.2522 • E-mail jmcdermott@dresources.com
                                   For questions regarding sales, service, and technical support, contact:
             United States: Tel +1.781.296.2662 • Fax +1.781.296.2550 • Europe: Tel +32.2.357.06.16 • Fax +32.2.351.2347
                                            Japan: Tel +81.3.5401.2615 • Fax +81.3.5401.2617

                                                                 3-1
    Scope:
      • Influenza disease and prevention: Occurrence and impact of seasonal and pandemic influenza
        infections, emerging pandemics, the threat and impact of the H5N1 avian flu virus.
      • The 2009 A/H1N1 pandemic: Threat, spread, and results of 2009 A/H1N1 infections, government
        response, vaccine approvals.
      • Impact of 2009 A/H1N1: Vaccine shortages and surpluses, financial impact on vaccine manufac-
        turers, Decision Resources’ Pharmaview historical sales data and forecast for influenza vaccines.
      • Egg-based manufacturing methods: Strain identification, seed production, production methods,
        drawbacks.
      • Mammalian-cell-based methods: Production processes, cell lines, Novartis, Baxter International,
        Solvay Pharmaceuticals, Crucell.
      • Emerging technologies: Baculovirus production systems, recombinant antigens, virus-like
        particles, toll-like-receptor-based platform, universal vaccines, DNA vaccines, Protein Sciences,
        Novavax, VaxInnate, Dynavax, Vical.
      • Outlook for influenza vaccine manufacturing: Impact of drawbacks on current methods, promo-
        tion and development of cell-based methods, adjuvants, emerging markets.

    Mentioned in This Report:
      •   Abbott Laboratories              •   ID Biomedical                    •   Select Vaccines
      •   Antigen Express                  •   Immune Targeting Systems         •   ShanH
      •   AstraZeneca                      •   Inovio Biomedical                •   Shantha Biotechnics
      •   Avimex Laboratories              •   Intercell                        •   Shenzen Neptunus Interlong
      •   Baxter International             •   Isconova                             Biotechnique
      •   Bharat Biotech                   •   Johnson & Johnson                •   Sinovac Biotech
      •   Biological E                     •   Juvaris BioTherapeutics          •   Solvay Biologicals
      •   Cadila Pharmaceuticals           •   Lentigen                         •   Solvay Pharmaceuticals
      •   Chiron                           •   MedImmune (AstraZeneca           •   TechnoVax
      •   CPL Biologicals                      subsidiary)                      •   Theraclone Sciences
      •   Crucell                          •   Merck & Co.                      •   UMN Pharma
      •   CSL Biotherapies                 •   Merieux Alliance                 •   Vaxart
      •   Dynavax Technologies             •   Mucosis                          •   Vaxine
      •   DynPort Vaccine Company          •   NanoBio                          •   VaxInnate
      •   Eurocine Vaccines                •   Neugenesis                       •   Vical
      •   FluGen                           •   Novartis                         •   ViraBiotech
      •   Folia Biotech                    •   Novavax                          •   Vivaldi Biosciences
      •   GE Healthcare                    •   PaxVax                           •   Vivalis
      •   Generex Biotechnology            •   Protein Sciences                 •   Xcellerex
      •   GlaxoSmithKline                  •   Roche                            •   Zhejiang Tianyuan
      •   GlobeImmune                      •   Sanofi Pasteur                        BioPharmaceuticals
      •   iBioPharma                       •   Sanofi-Aventis


    Key Terms for This Report:
    A/H1N1, Baculovirus, Cell-based, Celvapan, Crucell, Dynavax, Influenza, Novavax, Optaflu,
    Pandemic, Protein Sciences, Swine flu, Universal vaccine, Vaccine, VaxInnate




Decision Resources                                                                                          3-2
   Look for relevant insight within these Spectrum series and
   related Spectrum reports:

   Discovery and Innovation: Technologies, Strategies, and Dealmaking identifies and
   evaluates cutting-edge technologies for drug discovery and design and examines the
   impact that new technologies will have on the pharmaceutical R&D process. Our analyses
   identify the innovators who are developing the hottest technologies and help you to make
   important business development and licensing decisions to capitalize on these game-
   changing processes.


   Select titles from Discovery and Innovation: Technologies, Strategies, and
   Dealmaking:
     •   Investment and Dealmaking Trends in Biotechnology
     •   Can Innovative Technology Platforms Improve R&D Productivity?
     •   Insights into Platform Technology and Early-Stage Pipeline Mergers and Acquisitions
     •   New Strategies in Academic-Industry Collaborations
     •   Strategies for Building Early-Stage Pipelines Through External Sources
     •   Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?


   Therapeutic Markets – Opportunities and Pipeline Analysis provides comprehensive
   review and analysis of a wide range of drug classes and therapeutic indications, including
   major disease states, orphan diseases, and niche markets, with an emphasis on key
   established and emerging players. The insights contained in these reports will help you
   understand specific marketplaces and shape your strategy to maximize the commercial
   potential of your pipeline.


   Select titles from Therapeutic Markets – Opportunities and Dynamics:
     •   SPECIAL REPORT: Opportunities and Market Outlook in Respiratory Syncytial Virus
     •   SPECIAL REPORT: Gardasil Versus Cervarix in the Human Papillomavirus Market
     •   SPECIAL REPORT: The Pandemic Paradigm—Balancing Commercial Opportunities
         with Public Health Concerns in the Face of A/H1N1 2009
     •   Emerging Pharmaceutical Blockbusters: 2010’s Billion-Dollar Babies

   Strategic Overview of the Antivirals Marketplace
   Sales of Roche’s Tamiflu increased 435% in 2009 as a result of the H1N1 pandemic,
   highlighting the revenue potential of the marketplace but also the vagaries that make
   this arena a challenging one. What issues are companies active in this marketplace
   confronting? What strategies are they employing to compete successfully? What is the
   status of R&D? This comprehensive strategic overview -- which incorporates the insights
   of 100 board-certified U.S. infectious disease specialists -- explores a range of issues
   relevant to competitors: early-stage R&D targets and approaches; clinical pipelines by
   company, target, phase, and more; the role of diagnostics in drug development and
   deployment; dealmaking trends; leading companies; and the pricing and reimbursement
   environment, including the role of generics.



Decision Resources                                                                              3-3

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:12
posted:11/6/2011
language:English
pages:3